Goldenwell Biotech, INC

Goldenwell Biotech, Inc. announced a change in its independent registered public accounting firm, with KCCW Accountancy Corp. resigning and Michael Gillespie & Associates, PLLC appointed, following KCCW's going concern warning.

Goldenwell Biotech dismisses Michael Gillespie & Associates as their independent auditor and appoints KCCW Accountancy Corp. effective January 23, 2025.

Goldenwell Biotech has dismissed Yusufali & Associates as its auditor after the PCAOB revoked their registration, and has engaged Michael Gillespie & Associates as its new auditor.

Goldenwell Biotech has dismissed BF Borgers CPA PC as its independent auditor and appointed Yusufali & Associates, LLC, effective May 15, 2024.

Goldenwell Biotech, Inc. filed its Q2 2026 10-Q, revealing no revenue, a significant accumulated deficit, and substantial doubt regarding its ability to continue as a going concern, though it did report a minor other income from a legal settlement.

Goldenwell Biotech, Inc. has restated its Q3 2025 financial statements due to accounting errors related to legal fees, service revenue recognition, and prepaid fees.

Goldenwell Biotech, Inc. has issued an amendment to its Q2 2025 Form 10-Q to restate financial statements due to accounting errors.

Goldenwell Biotech, Inc. has issued an amendment to its Q1 2025 Form 10-Q to restate financial results due to an accounting error regarding legal expenses.

Goldenwell Biotech reported a reduced net loss in Q3 2025, driven by new service revenue, but faces significant liquidity challenges and ineffective disclosure controls.

Goldenwell Biotech reported a reduced net loss and increased cash in Q2 2025, but faces significant capital needs and ongoing going concern doubts with zero product sales.

Goldenwell Biotech's 2024 10-K filing reveals continued losses, minimal revenue, and substantial doubt about its ability to continue as a going concern.

Goldenwell Biotech's 2023 annual report reveals ongoing losses and a dependence on future financing, raising concerns about the company's ability to continue as a going concern.